Widespread Deregulation of Phosphorylation-Based Signaling Pathways in Multiple Myeloma Cells: Opportunities for Therapeutic Intervention

Gwenny Manel Fuhler,1* Sander Henricus Diks,2* Maikel Petrus Peppelenbosch,1† and William Garrow Kerr3†

1Department of Gasteroenterology and Hepatology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands; 2Department of Cell Biology, Section of Immunology, University Medical Center Groningen, Hanzeplein, Groningen, the Netherlands; 3Departments of Pediatrics and Microbiology & Immunology, SUNY Upstate Medical University, Syracuse, New York, United States of America

Multiple myeloma (MM) is a neoplasm of plasma cell origin that is largely confined to the bone marrow (BM). Chromosomal translocations and other genetic events are known to contribute to deregulation of signaling pathways that lead to transformation of plasma cells and progression to malignancy. However, the tumor stroma may also provide trophic support and enhance resistance to therapy. Phosphorylation of proteins on tyrosine, serine and threonine residues plays a pivotal role in cell growth and survival. Therefore, knowing the status of phosphorylation-based signaling pathways in cells may provide key insights into how cell growth and survival is promoted in tumor cells. To provide a more comprehensive molecular analysis of signaling disruptions in MM, we conducted a kinase profile comparison of normal plasma cells and MM plasma cells as well as their surrounding cells from normal BM and diseased BM. Integrated pathway analysis of the profiles obtained reveals deregulation of multiple signaling pathways in MM cells but also in surrounding bone marrow blood cells compared to their normal counterparts. The deregulated kinase activities identified herein, which include the mTOR (mammalian target of rapamycin)/p70S6K and ERK1/2 (extracellular signal-regulated kinases 1 and 2) pathways, are potential novel molecular targets in this lethal disease.

© 2011 The Feinstein Institute for Medical Research, www.feinsteininstitute.org
Online address: http://www.molmed.org
doi: 10.2119/molmed.2011.00013

INTRODUCTION

Multiple myeloma (MM) is a plasma cell (PC) neoplasm that leads to renal failure, hypercalcemia and skeletal destruction resulting in a median length of survival at diagnosis of approximately 3–5 years (1). There are thought to be three general categories of factors that promote the growth and/or survival of MM cells in vivo (2,3). The first consists of factors such as interleukin 6 (IL-6), IL-10 and interferon-α that trigger JAK/STAT (janus kinase/signal transducer and activator of transcription) pathways, which can lead to activation of mitogen-activated protein (MAP) kinases that drive cell proliferation. In addition, insulinlike growth factor (IGF)-1, HGF (hepatocyte growth factor) and EGF (epidermal growth factor) family members that engage syndecan-1 are known to activate not only proliferative pathways via the MAP kinases, but also survival pathways via activation of the PI3K/Akt/mTOR pathway. The third pathway involves the B-lineage-specific BAFF (B-cell activating factor) and April receptors, whose ligands can trigger activation of PI3K/Akt and nuclear factor κ-light-chain-enhancer of activated B cells (NF-κB) activities that promote cell survival.

High-throughput analysis systems have defined the transcriptome and proteome of MM and other tumor cells (4–6). Novel insights in the MM transcriptome have led to the notion that the majority of transcripts are necessary to keep a cell functioning and could be regarded as the minimal transcriptome. Therefore small changes in the expression profiles in this part of the transcriptome can lead to significant differences in cell functioning (7). Hence, an equally, if not more important, goal is to define the activity of the proteins that control the status of signal-
ing pathways available in experimental models (8). Kinases, the enzymes that phosphorylate tyrosine, serine and threonine residues on other proteins, play a major role in controlling the status of signaling cascades that determine, for example, cell cycle entry and survival. Knowing the status of signaling pathways in MM cells and their supporting stroma could provide critical information for understanding MM cell survival in the bone marrow (BM). Thus, a comprehensive description of cellular metabolism could be a valuable complement to descriptions of the proteome and transcriptome. We have developed a novel array-based strategy that allows the simultaneous detection of enzymatic activities for the phosphorylation of different kinase substrates in one cell sample (9–11). Here we apply this technology to primary MM isolates to assess the differences in kinase activity between MM cells and their normal PC counterparts, in addition to stromal elements that may also have an impact on MM growth and survival. These large-scale kinome comparisons reveal multiple, deregulated signaling pathways in MM and the surrounding BM blood cells and reveal potential novel avenues for therapy in this deadly blood cell cancer.

MATERIALS AND METHODS

Patient Samples

For cell sorting, MM primary patient samples were obtained from the liquid tissue acquisition core at the H. Lee Moffitt Cancer Center. Mononuclear cells were collected by the tissue acquisition staff via ficoll-gradient centrifugation. For normal PC sorts and phosphoflow, normal human BM samples were received as mononuclear cell suspensions in Hanks’ balanced salt solution with 5 mmol/L EDTA and 0.5% bovine serum albumin (1M-125; Lonza-Poietics, Basel, Switzerland). For phosphoflow analysis, non-MM and MM samples were obtained from the Frozen Liquids Tissue Core at the H. Lee Moffitt Cancer Center.

Fluorescence-Activated Cell Sorting

The populations of interest were sorted from both the MM and the normal human BM mononuclear cells in the same manner. The Fc receptors were blocked with anti-human CD32, and the sample was stained with anti-human CD38-fluorescein isothiocyanate (FITC), anti-human CD38-phycoerythrin (PE) and DAPI (4’6-diamidino-2-phenylindole-2HCl). The CD38+CD138+ and CD38+CD138− populations were collected separately by use of fluorescence-activated cell sorting (FACS) with an FACSARia (BD, Franklin Lakes, NJ, USA).

FACS Analysis

Cell surface marker expression on non-PC was analyzed by staining BM mononuclear cell fractions with the following antibodies: CD45-FITC, CD19-FITC, CD34-FITC, CD3-FITC, CD41a-APC, CD14-FITC, CD71-FITC, CD33-FITC, CD138-FITC, CD11b-FITC, CD36-FITC, VCAM-FITC (CD106) or glycoporphin A (GPA)-PE. To exclude PC and dead cells, samples were simultaneously stained for CD38-PE or CD38-FITC and DAPI.

Phosphoflow

The phosphoflow monoclonal antibody anti-ERK1/2/p(T202/p Y204), conjugated to Alexa Fluor 647, was purchased from BD Pharmingen (San Diego, CA, USA). Cells were stained with CD38, CD138 and p-ERK, or the appropriate isotype control according to the manufacturer’s protocol for phosphoflow analysis of human peripheral blood mononuclear cells.

Determination of the Phosphoproteome

Each of the MM or normal BM (NB) isolates prepared were applied to a PepChip slide. The PepChip used for profiling is the kinase v1 version containing duplicates of 1176 spots (1152 plus 24 control spots) derived from the annotated PhosphoBase (version 2.0) (57). Information on phosphorylation sites can be obtained through http://www.hprd.org/.

For the array samples, 0.5 × 10⁶ cells were lysed in cell lysis buffer (20 mmol/L Tris-HCl, pH 7.5, 150 mmol/L NaCl, 1 mmol/L Na₂EDTA, 1 mmol/L EGTA, 1% Triton X-100, 2.5 mmol/L sodium pyrophosphate, 1 mmol/L MgCl₂, 1 mmol/L beta-glycerophosphate, 1 mmol/L Na₃VO₄, 1 mmol/L NaF, 1 μg/mL leupeptin, 1 μg/mL apro tin, 1 mmol/L phenylmethylsulfonyl fluoride), and debris was removed by centrifugation. The peptide array incubation mix was produced by adding 10 μL of filter- cleared activation mix (50% glycerol, 50 μmol/L ATP, 0.05% v/v Brij-35, 0.25 mg/mL bovine serum albumin) and 2 μL [γ-³²P] ATP (approximately 1000 kBq; Amersham AH9968, Amersham Biosciences, Piscataway, NJ, USA) Next, the peptide array mix was added onto the chip, and the chip was kept at 37°C in a humidified incubator for 90 min. Subsequently the peptide array was washed twice with Tris-buffered saline with Tween 20, twice in 2 mol/L NaCl, and twice in demineralized H₂O, and then air-dried. The chips were exposed to a phosphoimager plate for 72 h, and the density of the spots was measured and analyzed with array software (ScanAnalyze).

Data Analysis

The 5% and 95% intervals of the spot density were calculated for each data set, and all spots were normalized within the boundaries for which the 5% level equals 0 and 95% is given the value 100. If only background phosphorylation is present, this amplitude-based distribution can be described by a single exponent. Because at low intensities of phosphorylation the contribution of biological phosphorylation is minimal, and hence the data in this range contain almost exclusively pure noise, we determined the exponent describing the amplitude behavior of the 250 least phosphorylated peptides, ranked from lowest to highest intensities, to give an adequate description of array background phosphorylation. True phosphorylation events were considered to have occurred for peptides of which the average phosphorylation minus z times the
SD was higher than the value expected from describing the background distribution. For integrated pathway analysis, $z$ was a floating value designed to maximize difference between the kinomes; for all other analyses $z$ was set to 1.96, which yielded a $P$ value of 0.05 or better for each “on” call made. The set of peptides that thus showed statistically significant phosphorylation compared to the background was then subjected to elective Markov analysis, i.e., assuming that different peptides acting as substrates for the same kinase have different affinity for phosphorylation by this kinase, kinases more active in one condition compared to another condition should display in the more active condition more phosphorylated target peptides. Thus the extent to which a kinase activity can be determined precisely is dependent on the number of substrates for the kinase (hence analysis for epidermal growth factor receptor (EGFR), for which only 2 peptides are present on the chip, is much more imprecise than analysis for protein kinase B, for which >15 peptides are present).

**Western Blot Analysis**

Sorted cells were lysed in cell lysis buffer as described above. Protein concentration was determined by bicinchoninic acid protein assay (Pierce, Rockford, IL, USA) according to the manufacturer’s instructions. Laemmli sample buffer was added to the samples and sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS-PAGE) and immunoblotting were performed as described (58). Detection was performed according to the manufacturer’s guidelines (ECL, Pierce, Rockford, IL, USA). All phosphoantibodies were from Cell Signaling Technology (Beverly, MA, USA). Membranes were reprobed with an antibody against actin (Santa Cruz Biotechnology, Santa Cruz, CA, USA), and densitometry of the blots was performed using ImageMaster 1D Elite (Pharmacia, Woerden, the Netherlands).

**Cell Viability Assay**

MM cell lines RPMI8226, U266 and OPM2 were routinely maintained in RPMI1640 (PAA Laboratories, Etobicoke, Ontario, Canada) supplemented with 10% fetal calf serum (PAA Laboratories). Cells were treated in duplicate for 36 h with increasing concentrations of sirolimus (LC Laboratories, Woburn, MA, USA), U1026 (Cell Signaling Technology) or protein kinase G (PKG) inhibitor (Calbiochem, Merck, Darmstadt, Germany). 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) (Sigma, St Louis, MO, USA) was added at a concentration of 0.5 mg/mL to the cells for 3 h. Formed crystals were dissolved in dimethyl sulfoxide and optical density (OD) was measured at 570 nm. The OD of compound treated cells was divided by the OD of their vehicle control, and the viability was expressed as a percentage of untreated cells. Results are expressed as mean ± SEM of three individual experiments.

All supplementary materials are available online at www.molmed.org

**RESULTS**

**Comparison of MM and NBM PC Kinome**

MM cells present in BM can be identified by the expression of high levels of CD38 and CD138 (12). CD38<sup>+</sup>CD138<sup>+</sup> MM cells from BM aspirates were obtained from 10 different patients and 10 different healthy BM donors with NBM (see representative Bone Marrow Sort, Supplementary Figure 1). We subsequently conducted a comparison of the kinase activities present in MM cells to those present in normal PC by applying PepChip array technology on the isolates. Figure 1A shows representative
RESEARCH ARTICLE

MOL MED 17(7-8)790-798, JULY-AUGUST 2011 | FUHLER ET AL. | 793

PepChip phosphorimager scans for purified MM and NBM PC from 2 of 10 different MM patients and 2 of 10 normal donors. In Figure 1B we show an MM versus a normal PC profile scatter plot in which each dot represents the normalized mean phosphorylation level for each of the 1152 substrates arrayed in duplicate on the PepChip for all MM cell and normal PC samples analyzed. As expected there is a great deal of similarity between the two kinomes; however, there is also a distinct subset of substrates that fall off the diagonal. Among these are the p70S6K target ribosomal protein S6 and the insulin receptor, the phosphorylation of which was increased in MM PC (Figure 1B). The insulin receptor shares 60% homology with the IGF-1 receptor, and binding of IGF-1 leads to its autophosphorylation and activation. IGF-receptor signaling is one of the most important growth, survival and migration signals for MM PC, and numerous groups have reported autocrine IGF-1 production for primary MM cells and myeloma cell lines (13,14).

Characterization of the Deregulated Kinome in MM Plasma Cells

Next, the normalized values were subjected to Markov analysis, which resulted in the generation of an “on” or “off” call for each kinase substrate, much like what is generally done for gene expression profiling, representing phosphorylation events that were significantly above background. To obtain a first insight into the characteristics of the PC kinome in general and the differences between the PC kinome and the MM kinome in particular, we performed an integrated pathway analysis using a floating value of $z$ (see Materials and Methods) to maximize the contrast between the two datasets. The results are presented in Supplementary Figure 2, which depicts for the two cell types for different kinases the fraction of kinase substrates receiving an “on” call. These results show that the differences between the two kinomes are mainly localized to the activation of the mTOR signaling pathway and the MAP kinase pathway.

Upregulation of the mTOR-p70S6K-S6 and ERK1/2 Pathways in MM PC

In MM but not NBM PC, PepChip data showed significant phosphorylation of the Ser133 target sequence of CREB, a known substrate for S6K and the MAPK ERK1/2, suggesting an enhanced constitutive activity of these pathways in MM cells. To validate this in a method independent of PepChip analysis, we sorted CD38hiCD138+ cells from two new MM patients and healthy donors, and compared the phosphorylation (and hence activation) status of the major molecules in this pathway according to Western blot analysis. Figures 2A and C show that phosphorylation levels of mTOR, p70S6K and S6 ribosomal protein, al-
though variable, as a mean were higher in MM PC compared with those in their normal counterparts.

To validate increased MAPK pathway activity in MM cells, we examined the level of MAPK phosphorylation in primary MM cells and normal PC by PhosphoFlow (Figure 2D). This analysis showed increased phosphorylation, and hence activity, of MAPK in MM cells compared with normal PC in both pairs of BM aspirates analyzed (Figure 2D, i,iii and ii,iii), consistent with our PepChip findings.

Next, we performed functional analysis of the dependence of MM cells on mTOR and MEK-ERK pathways for survival. Inhibition of either of these pathways with a selective inhibitor (i.e., sirolimus and U0126, respectively) decreases numbers of viable cells in three MM cell lines (Figure 3A, B). The data shown in Figure 3D demonstrate that treatment of MM cells with sirolimus inhibits constitutive and IGF-induced phosphorylation of both p70S6k and S6, but not ERK1/2. Vice versa, U0126 inhibits ERK1/2 phosphorylation, but not that of the p70S6k-S6 pathway. Interestingly, combined treatment at concentrations that induce very little cell death individually inhibited phosphorylation of both the p70S6k-S6 and ERK1/2 pathways, resulting in an additive effect on cell viability (Figure 3C). These data corroborate the notion that simultaneous inhibition of two independent survival pathways (i.e., p70S6k and ERK1/2) may be beneficial in the treatment of MM.

**Phosphoproteome of Normal PC**

The substrates that received an “on” call in NBM PC, but not in MM PC, included IL-1α, as well as the Src kinase substrate focal adhesion kinase (FAK), which activates the phosphorylation site Tyr577, and Annexin II. In light of the fact that PC from high-risk MM patients have been described to express high levels of IL-1α, this may seem surprising. IL-1 is thought to stimulate para- and autocrine IL-6 production in MM (15,16), and is a known physiological activator of NF-κB in B-lymphoid cells (17). Activation of NF-κB through FAK has been reported to play a role in IL-6 production in myoblasts (18). In addition, Src activity has been linked to NF-κB activity in mediating B-cell development (19). Activation of NF-κB requires its release from inhibitory factors, inhibitors of κB (IκBs), which are degraded upon phosphorylation by IκB kinases. We used Western blot analysis to compare IκB phosphorylation in three MM patients with that in two healthy controls, and we observed variable phosphorylation of IκB, with a higher mean densitometry in normal PC, suggestive of NF-κB activation (Figure 3B, C).

**Comparison of MM and NBM Non-PC Kinomes**

MM PC are known to influence their BM microenvironment directly, by cytokine production and stimulation of osteoclast activity, and indirectly, by physiological reduction of BM space by MM PC accumulation, resulting in impaired residual hematopoiesis. Indeed, by FACS analysis we observed significantly lower percentages of T cells (CD3+), early myeloid cells (CD33+) and granulocytic cells (CD11b+) in MM BM (n = 7) compared to normal BM (n = 6) (Supplementary Figure 3).

To determine whether there are significant signaling differences between the MM and normal BM microenvironment cells, we also sorted non-PC from 10 MM patients and 10 NBM donors (See Supplementary Figure 1 for an example of sorting and Figure 4A for representative PepChip phosphorimager scans). This fraction is enriched for cells from the erythroid lineage (CD36+, CD71+, GPA+).
resulted in an “on” call for 58 kinase substrates in MM non-PC, compared to 102 in NBM samples, with an overlap of 55 substrates (Supplemental Table S2). An “on” call was present for five vimentin-specific substrates in NBM CD38–CD138– cells, which were not present in MM stromal cells, a result that is strongly suggestive of a more adhesive phenotype in normal stromal cells. Vimentin is phosphorylated by active PAK2 kinase, and an increased phosphorylation (and hence activation) of PAK2 in CD38–CD138– cell lysates from two individual MM patients and two healthy BM donors was confirmed by Western blot analysis (Figure 5).

Whereas in PC, S6K and ERK signaling were increased in MM samples, the opposite was observed in non-PC samples. Two substrates for ERK1/2 kinase activity and one for 6S-kinase were phosphorylated in NBM cells, but not MM samples. In addition, phosphorylation of eukaryotic translation and initiation factor 4E, a target of the mTOR/p70S6K pathway, was also observed in normal CD38–CD138– cells. Western blotting indeed showed an increased phosphorylation of mTOR, p70S6K and S6 in normal stromal elements compared with MM non-PC, a finding indicative of activation of this pathway.

These results suggest widespread downregulation in signaling in MM BM cells, although the mixture of cell types present makes it impossible to assign kinase activity to individual populations and speculate on the meaning for these cell types. However, these results do demonstrate that in addition to MM PC, non-PC BM cells in general are also deregulated in MM patients.

**Common Targets in MM Plasma Cells and MM Stromal Cells**

In a final step we checked whether there are common substrates that are affected in both PC and stromal cells in MM. Correlation analysis of mean phosphorylation of substrates shows a high correlation between MM PC and NBM PC (0.92), and between MM non-PC and NBM non-PC (0.903). However, this high degree of correlation was not observed when PC and non-PC were compared in MM patients (0.77) or NBM (0.79), suggesting that PC have a kinome profile that is distinct from the rest of the BM. Per donor, correlations ranged from 0.667 to 0.89 for MM patients (mean 0.78 ± 0.072) and from 0.53 to 0.96 for NBM donors (mean 0.80 ± 0.14). No overlap was found between the substrates that received an “on” call in MM PC but not normal PC and those that were “on” in MM non-PC versus NBM non-PC. In contrast, of the 33 spots more strongly phosphorylated in NBM CD38hiCD138+ PC compared with MM PC, 25 (76%) were also upregulated in NBM CD38–CD138– non-PC compared with MM non-PC, indicating common deregulation of these pathways in both tumor and microenvironmental cells in MM BM. However, whereas 33 kinase targets were more phosphorylated in NBM PC, 102 spots were specifically upregulated in non-PC from healthy controls compared with their MM counterparts. This large difference might be the result of the presence of multiple individual cell types in the CD38–CD138– fraction, all contributing to the overall kinome profile. Of 189 target sequences phosphorylated in all four groups, i.e., PC and non-PC from MM and NBM, 43 received an “on” call in all of these. These sequences and the kinases they represent are likely the minimal kinome that is active in BM-derived cells.

**DISCUSSION**

We used the PepChip platform to determine which signaling pathways are deregulated in MM by directly comparing purified cell populations prepared from MM and normal BM isolates. We successfully demonstrated that the phosphoproteome of MM cells is significantly different from that of their normal PC counterparts. In MM PC, 64 kinase substrates were phosphorylated versus 88 in normal PC.
In non-PC, 58 kinase substrates received an “on” call in MM samples compared with 157 in NBM. These numbers demonstrate that kinase activity in general is dramatically decreased in diseased cells compared with normal cells. This result is somewhat surprising, because many studies have focused on inhibition of active signaling pathways as a strategy for treatment of this disease. However, most studies have focused either on stimulated kinase activity or on constitutive activity as a secondary result of another defect, such as deletion of the phosphatases PTEN (phosphatase and tensin homolog) or CD45 (20,21), which is not very common in MM (22). Our results suggest that although some pathways are highly constitutively activated in MM cells, the remaining kinome profile is repressed, a finding that may well reveal fundamental aspects of the transformed cells; the focus it has on proliferative pathways can result in a downregulation of other pathway activities, which are normally important in untransformed cells. In other words, the amount of energy available to a transformed cell may be redistributed to lead to overactivation of relatively few pathways, at a cost of other cellular signaling pathways. Similar results were demonstrated in acute myeloid leukemia (AML) cells, suggesting that this phenomenon might be common in hematological malignancies (A ter Elst, personal communication).

One of the phosphorylated substrates in MM PC was PKG, which has been best described regarding its role in mediating nitric oxide (NO) signaling (23). Hypoxic factors such as NO are capable inducers of angiogenesis, and NO signaling through PKG has been linked to insulin-induced production of vascular endothelial growth factor (VEGF-1) in smooth muscle cells (24). This potent angiogenic factor is also secreted by MM cells in response to IGF-1 stimulation, and increased VEGF-1 serum levels are correlated with poor prognosis in MM patients (25,26). Interestingly, malignant MM PC express high levels of nitrotyrosine, a marker of NO presence, and NO-synthase 1, 2 and 3. In addition, serum levels of NO are elevated in MM patients (25,26). Interestingly, orally tolerable NO-synthase inhibitors are available, and were shown to have antiangiogenic effects in a MM mouse model, reducing both tumor burden and VEGF production by MM cells (29). In addition to a role in angiogenesis, NO-activated PKG has also been implicated in antiapoptotic mechanisms in leukemic cells (30). We now show that chemical inhibition of PKG indeed reduces cell viability in three different MM cell lines (Supplementary Figure 4). Therefore, it is interesting to speculate on a potential benefit of NO-synthase or PKG inhibitors in the treatment of MM.

Our data showed an “on” call for FAK, Src kinase and IL-1α in normal PC, but not MM PC, in conjunction with an increased phosphorylation of IkB phosphorylation, suggestive of NF-κB activity. However, several studies have shown that NF-κB activation is present in MM cells. Inhibitors of this pathway, such as the proteasome inhibitor Bortezomib, which inhibits NF-κB activity by preventing degradation of IkB, have been shown to be of clinical benefit in 35% of patients (31). Our results might be explained by the fact that MM can be a heterogeneous disease, and in our analysis we show only substrates that were as a mean activated in 10 individual donors. In other words, although individual MM patients might present with increased NF-κB activity, this might not show up in a cross-examination of 10 patients. Furthermore, proteasome inhibitors are most effective when used in cotreatment strategies (32,33). Recently it was reported that NF-κB activity in MM cells was enhanced by conventional drugs like melphalan and doxorubicin, and was subsequently inhibited by proteasome inhibitors like Bortezomib (34). Because our MM samples were obtained at diagnosis, this might explain why we do not find an enhanced IkB phosphorylation in these patients.

Our analysis of the deregulated substrates in MM PC showed increased MAPK and mTOR/p70S6K pathway activity. These changes, in combination with other mutations, might be sufficient to cause the MM cell to assume malignant properties. Alternatively, early re-
ports suggested that apoptosis induction in MM cells in response to therapeutic agents like dexamethasone was a result of downregulation by these agents of the MAPK and p70S6K pathways (35). Later studies indicated that inhibition of mTOR by rapamycin-sensitized MM cell lines and primary MM cells to dexamethasone treatment (36), which was also shown in an in vivo mouse model (37). Our study results showing increased (constitutive) phosphorylation of the mTOR-p70S6K-S6 pathway in primary MM PC, and the sensitivity of MM cells to sirolimus, provide a rationale and incentive for the use of mTOR inhibitors in the treatment of MM. Interestingly, phase I/II clinical trials are currently being performed with NVP-BEZ235, an orally bioavailable compound that has been shown to reduce mTOR activity and MM proliferation (38). However, in addition to mTOR, this drug also targets the PI3K pathway. Given that our PepChip analysis did not reveal a major deregulation of this pathway in an average of 10 MM patients, more specific inhibitors, targeting only mTOR and its downstream components, might be more beneficial owing to reduced off-target effects. In fact, such inhibitors, e.g., rapamycin and its analogues RAD001 and sirolimus, were found to be orally tolerated in a range of studies targeting solid tumors. Recently however, phase I clinical trials of temsirolimus have been initiated in cotreatment regimens for MM that involve dexamethasone, Bortezomib or Lenalidomide (39). Based on our data, the use of mTOR inhibitors might be further enhanced by cotreatment with specific ERK1/2 inhibitors. An oral small molecule MEK/ERK inhibitor, AZD6244, has entered phase I/II clinical trials in patients with solid tumors, and, based on our results, may be beneficial in MM patients (40).

We propose that therapeutic approaches to treat MM could use two different regimens. One regimen employs inhibitors against multiple targets in MM PC (for example, MAPK and mTOR), or uses an approach in which deregulated kinases in both MM cells and their stroma are targeted. With the second approach deregulated growth of MM cells is countered via direct inhibition and through a less favorable environment (poisoning both the seed and soil to eradicate tumor cells). In conclusion, our findings show that phosphoproteome determination is a valuable tool to generate a global view of kinases deregulated in MM and to provide putative targets for treatment.

DISCLOSURE

The authors declare that they have no competing interests as defined by Molecula Medicine, or other interests that might be perceived to influence the results and discussion reported in this paper.

REFERENCES


